Raymond James Lowers DexCom (NASDAQ:DXCM) Price Target to $99.00

DexCom (NASDAQ:DXCM) had its target price lowered by equities research analysts at Raymond James from $115.00 to $99.00 in a report issued on Friday, Benzinga reports. The firm currently has a “strong-buy” rating on the medical device company’s stock. Raymond James’ target price indicates a potential upside of 34.80% from the company’s previous close.

DXCM has been the topic of a number of other research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price objective on shares of DexCom in a report on Tuesday, July 23rd. JPMorgan Chase & Co. increased their price target on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday. Stifel Nicolaus boosted their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. UBS Group lowered their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Finally, Robert W. Baird lifted their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Stock Down 1.9 %

Shares of NASDAQ:DXCM opened at $73.44 on Friday. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock has a market cap of $29.43 billion, a price-to-earnings ratio of 45.33, a price-to-earnings-growth ratio of 2.26 and a beta of 1.18. The firm’s 50 day moving average price is $70.11 and its 200 day moving average price is $98.24.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 24th. The medical device company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. The business had revenue of $994.20 million for the quarter, compared to analyst estimates of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. As a group, equities research analysts predict that DexCom will post 1.69 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,824 shares of company stock worth $126,390 over the last 90 days. 0.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DexCom

Several institutional investors have recently made changes to their positions in DXCM. Canada Pension Plan Investment Board increased its holdings in shares of DexCom by 189.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after purchasing an additional 435,401 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after buying an additional 353,019 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of DexCom by 53.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after acquiring an additional 345,114 shares during the period. Bellevue Group AG boosted its stake in shares of DexCom by 33.5% during the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock worth $169,380,000 after acquiring an additional 306,604 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new stake in shares of DexCom in the 2nd quarter worth approximately $31,793,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.